Tetsuya Mishima
Director/Board Member at Anaeropharma Science, Inc.
Profile
Tetsuya Mishima is currently the Representative Director at Anaeropharma Science, Inc. He previously held positions as Director at CellGenTech, Inc. and Partner at Watervein Partners KK.
Prior to his current and former positions, he worked as a Principal at Bank of America Corp.
Mishima received his undergraduate and graduate degrees from Tokyo Institute of Technology.
Tetsuya Mishima active positions
| Companies | Position | Start |
|---|---|---|
Anaeropharma Science, Inc.
 Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Director/Board Member | - |
Watervein Partners KK
 Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Private Equity Investor | 2002-08-31 |
CellGenTech, Inc.
 CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Director/Board Member | 2004-12-31 |
Former positions of Tetsuya Mishima
| Companies | Position | End |
|---|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Corporate Officer/Principal | - |
Training of Tetsuya Mishima
| Tokyo Institute of Technology | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MERRILL LYNCH PREFERRED CAPITAL TRUST I | Finance |
| Private companies | 3 |
|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
CellGenTech, Inc.
CellGenTech, Inc. Pharmaceuticals: MajorHealth Technology CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan. | Health Technology |
Watervein Partners KK
Watervein Partners KK Investment ManagersFinance Watervein Partners KK (Watervein Partners) is an independent venture capital firm headquartered in Tokyo, Japan. The firm was founded in 2002 by Kuroishi Masafumi. | Finance |
- Stock Market
- Insiders
- Tetsuya Mishima
